Moreover, LSD1 ablation overcame the resistance to anti-PD-1 therapy in a model of checkpoint blockade-refractory mouse melanoma, suggesting LSD1 inhibition in combination with PD-(L)1 blockade as a novel cancer treatment [188]. Here, KDM1A is linked to cancer.